Last reviewed · How we verify
Pseudoephedrine / Levocetirizine
This combination drug reduces nasal congestion via pseudoephedrine (a sympathomimetic decongestant) and allergic symptoms via levocetirizine (a selective H1-receptor antagonist).
This combination drug reduces nasal congestion via pseudoephedrine (a sympathomimetic decongestant) and allergic symptoms via levocetirizine (a selective H1-receptor antagonist). Used for Allergic rhinitis with nasal congestion.
At a glance
| Generic name | Pseudoephedrine / Levocetirizine |
|---|---|
| Also known as | Cossac L |
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Drug class | Decongestant/antihistamine combination |
| Target | Alpha-1 adrenergic receptor (pseudoephedrine); H1 histamine receptor (levocetirizine) |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | Phase 3 |
Mechanism of action
Pseudoephedrine acts as an alpha-adrenergic agonist that constricts blood vessels in the nasal mucosa, reducing swelling and congestion. Levocetirizine is the active S-enantiomer of cetirizine, a second-generation antihistamine that selectively blocks H1 receptors to reduce histamine-mediated allergic responses including itching, sneezing, and rhinorrhea. Together, they provide dual symptomatic relief for allergic rhinitis with nasal congestion.
Approved indications
- Allergic rhinitis with nasal congestion
Common side effects
- Headache
- Insomnia or nervousness
- Dry mouth
- Tachycardia
- Somnolence
Key clinical trials
- Parallel, Double-dummy, Superiority Study Levocetirizine/Pseudoephedrine x Zina for Allergic Rhinitis in Brazil (PHASE3)
- Comparison of the Effects for Lightening the Shiners Among Different Treatments for Rhinitis (NA)
- Efficacy and Cost Analysis of Steroids in Treatment of Otitis Media With Effusion (PHASE4)
- Efficacy/Safety of Pseudoephedrine Plus Levocetirizine Versus Placebo in Patients With Vasomotor Rhinitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: